Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5121668 | 0.86 | GAA (0.43) | BRD4TOP2ANR1H4GAAKDM4E | |
| SCHEMBL5127334 | 0.85 | GAA (0.60) | TOP2ANR1H4TRPA1ADRA1BGAA | |
| SCHEMBL5128146 | 0.83 | NR1H4 (0.64) | NR1H4GAAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5127402 | 0.81 | SALL4 (0.50) | BRD4TOP2AADRA1BGAAKDM4E | |
| SCHEMBL5116819 | 0.80 | SMN1; SMN2 (0.48) | ADRA1BGAAKDM4EALDH1A1GFER | |
| Hydrochloric Acid SCHEMBL5121300 | 0.80 | ADRA1B (0.50) | BRD4TOP2AADRA1BGAAKDM4E | |
| SCHEMBL5121581 | 0.80 | GAA (0.52) | BRD4ADRA1BGAAKDM4EALDH1A1 | |
| SCHEMBL5121834 | 0.80 | ADRA1B (0.34) | TOP2ATRPA1ADRA1BGAAKDM4E | |
| SCHEMBL5115623 | 0.80 | ADRA1B (0.52) | BRD4TOP2ANR1H4ADRA1BGAA | |
| SCHEMBL5116936 | 0.80 | NR1H4 (0.44) | NR1H4GAAALDH1A1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791840-B1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2013-11-27 | — | — | EP | claimed |
| US-7420056-B2 | Substituted bicyclic imidazo-3-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-09-02 | — | — | US | claimed |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | GRUENENTHAL GMBH. (DE) | 2007-07-05 | — | — | US | claimed |
| EP-1791840-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2007-06-06 | — | — | EP | claimed |
| WO-2006029980-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2006-03-23 | — | — | WO | claimed |
| US-7420056-B2 | Substituted bicyclic imidazo-3-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-09-02 | — | — | US | disclosed |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | GRUENENTHAL GMBH. (DE) | 2007-07-05 | — | — | US | disclosed |
| EP-1791840-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006029980-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | BRD4 83/4885TOP2A 2972/4885NR1H4 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.